{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:36:49Z","timestamp":1792773409216,"version":"4.5.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001922","name":"Efficacy and Mechanism Evaluation Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001922","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018601","name":"Wales Cancer Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR131082"],"award-info":[{"award-number":["NIHR131082"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.clon.2026.104311","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:17:54Z","timestamp":1785338274000},"page":"104311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["UK Photon Radiotherapy Practice for Oligodendroglioma \u2013Data From the Analysis of Proton vs Photon Radiotherapy in Oligodendroglioma and Assessment of Cognitive Health Trial (ISRCTN:1339049) Radiotherapy Quality Assurance (RTQA) Programme"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6667-2287","authenticated-orcid":false,"given":"J.","family":"Golten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Egleston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0645-4703","authenticated-orcid":false,"given":"E.","family":"Miles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clon.2026.104311_bib1","doi-asserted-by":"crossref","DOI":"10.1111\/nan.12432","article-title":"WHO 2016 Classification of gliomas","volume":"44","author":"Wesseling","year":"2018","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"14","key":"10.1016\/j.clon.2026.104311_bib2","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","article-title":"Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma","volume":"374","author":"Buckner","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clon.2026.104311_bib3","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1200\/JCO.2012.43.2229","article-title":"Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951","volume":"31","author":"Van den Bent","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clon.2026.104311_bib5","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1001\/jamaoncol.2017.0997","article-title":"Efficacy of Stereotactic Conformal Radiotherapy vs Conventional Radiotherapy on Benign and Low-Grade Brain Tumors: A Randomized Clinical Trial","volume":"3","author":"Jalali","year":"2017","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.clon.2026.104311_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-097810","article-title":"APPROACH: Analysis of Proton versus Photon Radiotherapy in Oligodendroglioma and Assessment of Cognitive Health - study protocol paper for a phase III multicentre, open-label randomised controlled trial","volume":"15","author":"Slevin","year":"2025","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.clon.2026.104311_bib7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.clon.2010.11.003","article-title":"Radiotherapy planning in high-grade gliomas: a survey of current UK practice","volume":"23","author":"Creak","year":"2011","journal-title":"Clin Oncol (R Coll Radiol"},{"issue":"2","key":"10.1016\/j.clon.2026.104311_bib8","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ijrobp.2012.11.031","article-title":"Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors","volume":"85","author":"Gondi","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.clon.2026.104311_bib9","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/ncpendmet1051","article-title":"Radiation-induced hypopituitarism after cancer therapy: who, how and when to test","volume":"5","author":"Darzy","year":"2009","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1016\/j.clon.2026.104311_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110594","article-title":"ESTRO-EANO guideline on target delineation and radiotherapy for IDH-mutant WHO CNS grade 2 and 3 diffuse glioma","volume":"202","author":"Baumert","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2026.104311_bib11","unstructured":"RCR Radiotherapy dose fractionation 4th ed https:\/\/www.rcr.ac.uk\/our-services\/all-our-publications\/clinical-oncology-publications\/radiotherapy-dose-fractionation-fourth-edition\/2024[accessed Sept 2025]."},{"issue":"8","key":"10.1016\/j.clon.2026.104311_bib12","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.clon.2010.06.014","article-title":"Radiotherapy Development Board. Survey of the availability and use of advanced radiotherapy technology in the UK","volume":"22","author":"Mayles","year":"2010","journal-title":"Clin Oncol (R Coll Radiol"},{"issue":"8","key":"10.1016\/j.clon.2026.104311_bib13","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0936-6555(03)00150-X","article-title":"Neuro-oncology practice in the UK","volume":"15","author":"Gerrard","year":"2003","journal-title":"Clin Oncol (R Coll Radiol"},{"key":"10.1016\/j.clon.2026.104311_bib14","series-title":"RCR clinical oncology Census","year":"2023"},{"issue":"5","key":"10.1016\/j.clon.2026.104311_bib16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.clon.2024.01.017","article-title":"The National Radiotherapy Trials Quality Assurance Group - Driving up Quality in Clinical Research and Clinical Care","volume":"36","author":"Miles","year":"2024","journal-title":"Clin Oncol (R Coll Radiol"},{"issue":"1","key":"10.1016\/j.clon.2026.104311_bib17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13014-019-1225-0","article-title":"Driving developments in UK oesophageal radiotherapy through the SCOPE trials","volume":"14","author":"Gwynne","year":"2019","journal-title":"Radiat Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526002827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526002827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T15:05:39Z","timestamp":1792767939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655526002827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":15,"alternative-id":["S0936655526002827"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2026.104311","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"UK Photon Radiotherapy Practice for Oligodendroglioma \u2013Data From the Analysis of Proton vs Photon Radiotherapy in Oligodendroglioma and Assessment of Cognitive Health Trial (ISRCTN:1339049) Radiotherapy Quality Assurance (RTQA) Programme","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2026.104311","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Royal College of Radiologists. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104311"}}